A great boom vaccination campaign is starting today in Harare to tackle the causes of drug-resistant disease.
The aim of the campaign is to vaccinate 325,000 people in nine suburbs of the Zimbabwe capital. The campaign will be the first in Africa to use a new Conjugate Typhoid Vaccine (TCV) which, unlike other cattle vaccines, is administered to young children and has a permanent immunity.
This is the second wave of Harare's great congestion cases that began in October 2017. This second wave began in September 2018 and has led to 1,810 cases and two deaths to date.
It is estimated that around one in five cases in Harare resist antibiotic ciprofloxacin – the first line of protection against the disease – with a scary disturbance of 73% in some areas. With genes that are resistant to cyclical drugs, there is a danger that resistance can grow.
"Although exhaustion vaccines have existed for over a century, they could not only offer short-term protection only, and could not be used to protect the most vulnerable to this serious disease: young children," said Dr Seth Berkley, CEO of Gavi, the League Vaccine. "These new vaccines will be a game changer, not only in the fight against catastrophe but also in the global effort to tackle drug resistance. They are now ready I used to include this serious cause in Zimbabwe is great news. "
The campaign will run until March 4 and will target 6 months to 15 year olds in the eight suburbs of Harare: Budiriro, Dzivarasekwa, Glen Norah, Glenview, Hatcliffe, Hopley, Mufakose, Kuwadzana. In the Mbare area, where the disease has affected adult populations, the campaign will target children as well as adults up to the age of 45. The campaign is mainly funded by Gavi, with additional funding from WHO, and is hosted by the Zimbabwe Ministry of Health, supported by WHO and CDC.
Vaccines are only a short-term solution to a confoot, although there is an important part of a wider management strategy. The best sustainable sustainable solution and investing in water and sanitation infrastructure is only in the long term. When a community with clean water and good hygiene, the spread of fertilizer is limited.
In November 2017 the Gavi Board agreed to open a financing window of US $ 85 million to pay for the introduction of the new Growth Combination Vaccine. Bharat Biotech International Limited became the first company to obtain a qualifying vaccine from WHO in December 2017, and subsequently Gavi began to receive applications from countries for funding. This campaign in Harare is the first to be funded by Gavi. The Zimbabwe government is now working with partners, including Gavi, on the possible introduction of TCV in its normal normal immunization program.
The two globes and tephoids are endemic to Harare. The causes of both diseases have been associated with increased use of contaminated boreholes and bundles due to the lack of urban water in the city. Fatigue fever causes an estimated 11 to 21 million cases and 128,000 to 161,000 deaths worldwide worldwide. Severe complications of fetus include bowel perforation, hemorrhage of intestine, meningitis, hepatitis, coma and shock.